Core Viewpoint - Pfizer has lowered its FY2026 profit forecast due to declining Covid vaccine sales and impending patent expirations on key products, projecting profits between $2.80 and $3 per share, below analyst expectations of $3.05 per share [1] Financial Projections - The company anticipates FY2026 revenue to be between $59.5 billion and $62.5 billion, compared to analyst estimates of $61.59 billion [2] - Pfizer's FY2025 profit forecast has also been reduced to $62 billion, which is at the lower end of its previous guidance of $61 billion to $64 billion [6] Research and Development - R&D expenses are expected to range from $10.5 billion to $11.5 billion as Pfizer focuses on advancing its newly licensed PD-1xVEGF oncology asset and various clinical programs from the Metsera acquisition [3] Impact of Covid Vaccine Sales - Projected profits from Covid vaccine sales are expected to decline by $1.5 billion in 2026 compared to 2025 forecasts, reflecting a broader trend affecting other pharmaceutical companies [4] Patent Expirations - Pfizer estimates a loss of $1.5 billion in profit due to the expiration of market exclusivity for certain products, including the JAK inhibitor Xeljanz, blood thinner Eliquis, and cancer drug Ibrance [5] Cost-Cutting Measures - The company has initiated a cost-cutting strategy aimed at reducing spending by $7.7 billion by 2027, which includes cutting 230 jobs in Switzerland as part of a broader operational downsizing [7] Strategic Focus - Pfizer is targeting the weight loss market while implementing stringent cost-cutting measures and pursuing pipeline-enhancing deals [8]

Financial Guidance - Pfizer projects 2026 sales between $595 billion and $625 billion, roughly in line with street expectations but flat compared to the expected $62 billion for 2025 [2] - The company's profit guidance came in slightly below street expectations, at $280 to $300 per share [2] Revenue Challenges - Pfizer anticipates a $15 billion decrease in revenue from COVID products in 2026 compared to 2025 [3] - An additional $15 billion revenue hit is expected from upcoming patent expirations of older drugs [3] Mitigation Strategies - Analysts suggest the guidance reflects costs tied to recent acquisitions, including the obesity biotech Mitsera [4] - Pfizer is targeting more than $7 billion in cost savings by 2027 to partially offset revenue declines [4] Market Perception - The market did not appreciate Pfizer's 2026 guidance [1] - COVID weakness and deal dilution are still impacting Pfizer's performance [5]

Fizer falling after announcing its 2026 guidance. Our Anakica Kim Constantino has some details as the market didn't appreciate much what we got for the new year. Anakah, >> that's right, Carl.So, Fiser today issuing a modest 2026 guidance saying it expects sales to come in between 59.5% billion to 62.5% billion. And that's roughly in line with the street, but largely flat compared to the 62 billion in sales that expects for 2025. And in terms of its profit guidance, it came in slightly below what the street ...

Pfizer issued its 2026 guidance, expecting its adjusted earnings per share to come in below this year’s figures, and revised its 2025 revenue outlook https://t.co/pmHnDNPVYo ...

About this content About Angela Harmantas Angela Harmantas is an Editor at Proactive. She has over 15 years of experience covering the equity markets in North America, with a particular focus on junior resource stocks. Angela has reported from numerous countries around the world, including Canada, the US, Australia, Brazil, Ghana, and South Africa for leading trade publications. Previously, she worked in investor relations and led the foreign direct investment program in Canada for the Swedish government ...

（文章来源：每日经济新闻） 每经AI快讯，12月16日，辉瑞股价下跌5.2%，创4月10日以来最大盘中跌幅。 ...

格隆汇12月16日｜辉瑞股价下跌5.2%，创4月10日以来最大盘中跌幅。 ...

本文源自：金融界AI电报 辉瑞(PFE.N)股价下跌5.2%，创4月10日以来最大盘中跌幅。 ...

辉瑞股价下跌5.2%，创4月10日以来最大盘中跌幅。 来源：滚动播报 ...

周二，辉瑞(PFE.US)跌逾4%，报25.27美元。消息面上，辉瑞预测，随着该公司正努力通过一系列昂贵 的收购来更新其热门药物产品线，明年的销售增长将微乎其微甚至没有增长。辉瑞公司周二在一份声明 中表示，预计2026年营收将在595亿美元至625亿美元之间，与华尔街的预期大致相符。今年销售额预计 为620亿美元，与该公司11月初的指引范围一致。该公司预计明年调整后每股收益将位于2.80美元至3美 元之间。 首席执行官Albert Bourla正面临着重振辉瑞的关键时刻，因为几年前推动公司销售额激增的新冠疫苗和 治疗药物的需求正在消退新冠相关产品的收入仍在下降；辉瑞预测，明年这些产品的销售额将减少约15 亿美元至50亿美元。 ...